ATE535237T1 - Verwendung von fts zur behandlung von malignen erkrankungen - Google Patents

Verwendung von fts zur behandlung von malignen erkrankungen

Info

Publication number
ATE535237T1
ATE535237T1 AT10004111T AT10004111T ATE535237T1 AT E535237 T1 ATE535237 T1 AT E535237T1 AT 10004111 T AT10004111 T AT 10004111T AT 10004111 T AT10004111 T AT 10004111T AT E535237 T1 ATE535237 T1 AT E535237T1
Authority
AT
Austria
Prior art keywords
fts
malignant diseases
treat malignant
treatment
structural
Prior art date
Application number
AT10004111T
Other languages
English (en)
Inventor
Victor J Bauer
Original Assignee
Concordia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concordia Pharmaceuticals Inc filed Critical Concordia Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE535237T1 publication Critical patent/ATE535237T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT10004111T 2004-08-18 2005-08-18 Verwendung von fts zur behandlung von malignen erkrankungen ATE535237T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60236104P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
ATE535237T1 true ATE535237T1 (de) 2011-12-15

Family

ID=35447506

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05787786T ATE466574T1 (de) 2004-08-18 2005-08-18 Verfahren und zusammensetzungen zur oralen fts- abgabe
AT10004111T ATE535237T1 (de) 2004-08-18 2005-08-18 Verwendung von fts zur behandlung von malignen erkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05787786T ATE466574T1 (de) 2004-08-18 2005-08-18 Verfahren und zusammensetzungen zur oralen fts- abgabe

Country Status (9)

Country Link
US (4) US8088756B2 (de)
EP (3) EP2218451B1 (de)
AT (2) ATE466574T1 (de)
CA (1) CA2577310C (de)
DE (1) DE602005021115D1 (de)
ES (2) ES2414861T3 (de)
MX (1) MX2007001929A (de)
PL (1) PL1778209T3 (de)
WO (1) WO2006023639A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088756B2 (en) 2004-08-18 2012-01-03 Concordia Pharmaceuticals, Inc. Methods and compositions for oral delivery of FTS
ATE485037T1 (de) 2005-11-28 2010-11-15 Univ Ramot Krebsbehandlung mittels fts und 2-deoxyglucose
WO2007091241A1 (en) * 2006-02-10 2007-08-16 Ramot At Tel Aviv University Ltd. Treatment of ovarian cancer
US20110046223A1 (en) * 2006-06-14 2011-02-24 Ramot At Tel-Aviv University Ltd. Treatment of neurofibromatosis
EP2094260B1 (de) * 2006-12-19 2012-02-01 Ramot at Tel-Aviv University Ltd. Behandlung von lungenkrebs
WO2011056542A1 (en) * 2009-10-26 2011-05-12 Ramot At Tel-Aviv University Ltd. Cancer therapy with combinations of fts with hdac inhibitors
US9309203B2 (en) 2011-10-07 2016-04-12 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
CA3227706A1 (en) * 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL107587A (en) * 1993-11-12 1998-08-16 Univ Ramot Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
WO1999050388A1 (en) * 1998-03-27 1999-10-07 Chong Kun Dang Corporation Streptomyces sp. producing tautomycetin and immunosuppressant comprising tautomycetin as active ingredient
US20020115696A1 (en) * 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
CA2377254C (en) * 1999-06-18 2009-08-18 Thyreos Corporation Non-malignant disease treatment with ras antagonists
US20040072258A1 (en) * 2000-10-04 2004-04-15 Yoel Kloog Isoprenoid-dependent ras anchorage (idra) proteins
US20020169183A1 (en) * 2001-03-08 2002-11-14 Villar Hugo O. Acridines as stimulators for Fas-mediated apoptosis
EP1390472A4 (de) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc Nukleinsäurebehandlung von krankheiten oder leiden im zusammenhang mit ras-, her2- und hiv-niveaus
EP1604037A1 (de) * 2003-03-20 2005-12-14 Universite Catholique De Louvain Medizinische verwendung von ras antagonisten zur behandlung von kapillaren schäden
US20070054886A1 (en) * 2003-05-23 2007-03-08 Ramot At Tel Aviv University, Ltd. Ras antagonists for treating neurodegenerative disorders
WO2005018562A2 (en) * 2003-08-22 2005-03-03 University Of Virginia Patent Foundation Blockade of mtor to prevent a hormonal adaptive response
US8088756B2 (en) 2004-08-18 2012-01-03 Concordia Pharmaceuticals, Inc. Methods and compositions for oral delivery of FTS
ATE485037T1 (de) 2005-11-28 2010-11-15 Univ Ramot Krebsbehandlung mittels fts und 2-deoxyglucose

Also Published As

Publication number Publication date
EP1778209B8 (de) 2010-06-16
DE602005021115D1 (de) 2010-06-17
EP1778209A1 (de) 2007-05-02
US8088756B2 (en) 2012-01-03
CA2577310A1 (en) 2006-03-02
EP2218451B1 (de) 2011-11-30
EP2218451A1 (de) 2010-08-18
US20090226512A1 (en) 2009-09-10
MX2007001929A (es) 2007-04-17
ATE466574T1 (de) 2010-05-15
EP2301528A1 (de) 2011-03-30
PL1778209T3 (pl) 2010-10-29
US20160271089A1 (en) 2016-09-22
US20150191426A1 (en) 2015-07-09
WO2006023639A1 (en) 2006-03-02
US20120082722A1 (en) 2012-04-05
ES2343737T3 (es) 2010-08-09
EP2301528B1 (de) 2013-04-03
ES2414861T3 (es) 2013-07-23
CA2577310C (en) 2011-01-11
EP1778209B1 (de) 2010-05-05

Similar Documents

Publication Publication Date Title
EA200400881A1 (ru) Азаарилпиперазины
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
EP1543158A4 (de) Regulierte aptamer-therapeutika
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
NO20080244L (no) Doseringsstyring for prasugrel
ATE398441T1 (de) Octenidinhaltige lutschtabletten gegen entzündliche erkrankungen des mund- und rachenraums
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
NO20071238L (no) Fremgangsmater for leging av skader ved human IL-18 administrering
EA201270298A1 (ru) Способ лечения злокачественной опухоли
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
ATE404519T1 (de) Hyperforinderivate, ihre verwendung sowie diese enthaltende zubereitungen
DE60236299D1 (de) Valeriana officinalis extrakt zur behandlung von schlafapnoe oder hypopnoe